# Junta clínica — PT-pseudo_83f690a06c81 (tarea 1)

## Intervención 1 — INTAKE

*the record clerk; reads the file out loud and interprets nothing* · vuelta 1

Colleagues, this is the record as it arrived, field by field. I read it out and interpret nothing; everything after this is yours.

{
  "case_id": "PT-pseudo_83f690a06c81",
  "pid": "PT-pseudo_83f690a06c81",
  "task": 1,
  "psa": 12.0,
  "age": 66,
  "months": 1,
  "pirads": "5",
  "psad": 0.173,
  "psav": 2.64,
  "psap": 9.0,
  "vol": 69.24,
  "dre": "Normal",
  "bx": "Positive",
  "cspca": 0.8477834,
  "medhx": "Not reported",
  "meds": "None",
  "notes": "PSA 12 ng/mL. PI-RADS 5. PSAD 0.17. Prostate volume 69 mL. csPCa 0.85.",
  "pmhx": [],
  "allergies": [],
  "vitals": {
    "weight": "70 kg",
    "height": "172 cm",
    "bmi": "23.7",
    "bp": "116/73 mmHg",
    "hr": "69 bpm",
    "smoking": "Non-smoker",
    "last_dental": "2 yr ago",
    "flu_vax": "Sep 2024"
  },
  "enc_dept": "Urology - outpatient",
  "enc_date": "15 Feb 2025",
  "enc_ref": "Dr. N. Kuiper (GP)",
  "enc_type": "Re-evaluation - prior PCa diagnosis",
  "note_sections": [
    {
      "s": "Chief complaint",
      "t": "Documented PSA escalation alongside a previously positive prostate biopsy warrants clinical reassessment."
    },
    {
      "s": "History",
      "t": "A 66-year-old graphic designer first entered diagnostic evaluation in early 2024 due to an elevated PSA, a value that has now advanced to 12.0 ng/mL. Lower urinary tract complaints are moderate, yielding an IPSS score of 16, with nocturia and a diminished stream being the primary concerns; he explicitly denies haematuria or pelvic discomfort. Leisure activities include tennis twice weekly, and his alcohol intake remains at approximately five units of alcohol per week. Systemic health remains stable, corroborated by an autumn 2024 cardiology review showing no significant deviations, routine dental maintenance, and a recent chest X-ray. He shares his home with his wife, while adult children stop by each week. Reaching the clinic requires a train journey lasting over an hour."
    },
    {
      "s": "Physical examination",
      "t": "Per rectum: the gland presents as symmetrically enlarged, exhibiting a smooth, firm consistency without nodularity or asymmetry. Vital parameters remain stable, recording a blood pressure of 116/73 mmHg and a regular heart rate of 69 bpm. Systemic examination reveals no pallor, lymphadenopathy, or abdominal masses."
    }
  ],
  "occupation": "graphic designer",
  "marital": "Married",
  "living": "Lives with partner; adult children visit weekly",
  "next_of_kin": "Long-time friend (no close family)",
  "recent_other": [
    "Cardiology — annual review (stable, autumn 2024)",
    "Dental — biannual check-up",
    "Radiology — chest X-ray (routine)"
  ],
  "alcohol": "5 units / week",
  "exercise": "Tennis 2x/week",
  "ipss": "IPSS score: 16/35 (moderate LUTS)",
  "admin": "Patient travels 60+ min by train to clinic; allow buffer.",
  "mri_hospital": "Radboudumc",
  "ct": null,
  "active_treatment_flag": 0
}

## Intervención 2 — INTAKE

*the record clerk; reads the file out loud and interprets nothing* · vuelta 1

And this is the same record as the reading form presents it — the panel the urologist sees up front, with the masked documents named but not shown.

You are a senior urologist reviewing a patient case. The structured clinical
record below is shown to you up front, exactly as in the reading form. Some
documents are not shown and must be pulled up via the available tools
(radiology / MRI report, pathology report, previous notes, laboratory
results, PSA history, and the family-history anamnesis) when you need to
consult them.

Case ID: PT-pseudo_83f690a06c81
Task: 1

Encounter: Urology - outpatient on 15 Feb 2025.
Referrer: Dr. N. Kuiper (GP).
Type: Re-evaluation - prior PCa diagnosis.

Clinical data (read-only — values loaded from the record):
  - 66-year-old male
  - PSA: 12.0 ng/mL
  - mpMRI — PI-RADS score: 5 (1–2 low · 3 equivocal · 4–5 high risk)
  - PSA density: 0.173 ng/mL²
  - PSA velocity: 2.64 ng/mL/yr
  - Prior PSA: 9.0 ng/mL
  - Prostate volume: 69.24 mL
  - Months since last PSA: 1
  - DRE findings: Normal (Normal · Nodus · Benign · Suspicious · Abnormal · Negative · Not done)
  - Prior biopsy: Positive (None · Negative · ASAP/HGPIN · Positive)
  - csPCa predicted probability: 0.8477834 (clinically significant PCa = ISUP ≥ 2)

Medical history & medication:
  - Medical history: Not reported
  - Problem list / PMHx: none recorded
  - Current medication: None
  - Allergies: NKA
  - Additional notes: PSA 12 ng/mL. PI-RADS 5. PSAD 0.17. Prostate volume 69 mL. csPCa 0.85.

Vitals: weight 70 kg, height 172 cm, BMI 23.7, BP 116/73 mmHg, HR 69 bpm. Smoking: Non-smoker.

Chief complaint: Documented PSA escalation alongside a previously positive prostate biopsy warrants clinical reassessment.

History: A 66-year-old graphic designer first entered diagnostic evaluation in early 2024 due to an elevated PSA, a value that has now advanced to 12.0 ng/mL. Lower urinary tract complaints are moderate, yielding an IPSS score of 16, with nocturia and a diminished stream being the primary concerns; he explicitly denies haematuria or pelvic discomfort. Leisure activities include tennis twice weekly, and his alcohol intake remains at approximately five units of alcohol per week. Systemic health remains stable, corroborated by an autumn 2024 cardiology review showing no significant deviations, routine dental maintenance, and a recent chest X-ray. He shares his home with his wife, while adult children stop by each week. Reaching the clinic requires a train journey lasting over an hour.

Physical examination: Per rectum: the gland presents as symmetrically enlarged, exhibiting a smooth, firm consistency without nodularity or asymmetry. Vital parameters remain stable, recording a blood pressure of 116/73 mmHg and a regular heart rate of 69 bpm. Systemic examination reveals no pallor, lymphadenopathy, or abdominal masses.

Patient info: graphic designer; Married; Lives with partner; adult children visit weekly.
Next of kin: Long-time friend (no close family).

Lifestyle: alcohol 5 units / week; exercise Tennis 2x/week; IPSS score: 16/35 (moderate LUTS).

Recent other appointments: Cardiology — annual review (stable, autumn 2024); Dental — biannual check-up; Radiology — chest X-ray (routine).
Admin: Patient travels 60+ min by train to clinic; allow buffer.

Information you can request via tools (the masked "Extended EHR view" — what
the urologist would actively pull up during the consult):
  - radiology / MRI report (full mpMRI prose behind the headline imaging values)
  - pathology report (any prior biopsy on record)
  - previous GP / urology consultation notes
  - laboratory results (full panel)
  - PSA history (trend / velocity beyond the headline value)
  - family history of prostate cancer (anamnesis)

Question:
Based on this patient's data, do you recommend biopsy?


One correction to that last paragraph before anybody acts on it: the documents this task actually serves are radiology_report, psa_trend, previous_notes, laboratory_results, plus the family-history anamnesis. There is NO pathology report to pull up in a task-1 biopsy decision — the prior-biopsy status on the panel above is all the pathology on record, and whatever the previous notes say about it. Nobody should ask for one, and nobody should quote one.

## Intervención 3 — EXPERT-STRUCTURED

*Expert 1, Extra-Trees on the structured panel only; opening bid with an error bar* · vuelta 1

Expert 1 here — the classifier that reads the structured panel and nothing else. My bid:

SUGGESTION: BIOPSY   p(biopsy) = 0.60
  uncertainty  +/- 0.10 epistemic (95% band 0.41-0.80); among patients I cannot tell apart the outcome was 0.97 of 1.00 mixed
  reliability  MODERATE ('supports' tier) — out-of-fold it was right 60% of the time over the 20 labelled cases in this tier

VARIABLES I WEIGHED — in the form's vocabulary, with this man's values (panel only; the levels are what moved my prediction across the series, not what a urologist would mark)
  decisive   prior biopsy = Positive (43% of my signal; from bx_positive, bx_none)
  important  comorbidity = none recorded (21% of my signal; from pmhx_hypercholesterolaemia, n_comorbidities)
  noted      age = 66 (2% of my signal; from age) · DRE = Normal (10% of my signal; from dre_suspicious) · PSA = 12 ng/mL (3% of my signal; from log_psa, psav) · prostate volume = 69.24 mL (1% of my signal; from log_vol, vol) · PSA density = 0.173 (0% of my signal; from psad_calc, log_psad) · csPCa probability = 0.85 (1% of my signal; from cspca) · PI-RADS = 5 (20% of my signal; from pirads_ge4, pirads_ge3)
  not used   family history
CONFIDENCE: borderline — 'supports' tier; out-of-fold it was right 60% of the time over the 20 labelled cases in this tier

I read 39 raw variables, all from the panel — nothing from the mpMRI prose, the PSA
trajectory, the previous notes or the laboratory. Out-of-fold over 91 labelled cases: AUC
0.758, balanced accuracy 0.625.
The final call is the chair's.

## Intervención 4 — EXPERT-COHORT

*cohort criterion; what the labelled series did in this exact situation* · vuelta 1

This patient's situation: prior positive biopsy. The panel alone does not answer, and that is the finding.

The criterion here is that the visible panel does not determine this decision: he already has a tissue diagnosis, so neither a high PI-RADS nor a rising PSA is new information. What decides it is the documented grade of the prior biopsy and the surveillance history, which live in the previous notes. Measured on the labelled series: none of the three panel
rules I carry for this situation (PSA >= 20, age >= 78, PI-RADS <= 2) applies to him, and among the
39 remaining labelled men in this situation no structured variable separates the two answers.

REGISTRAR: the previous notes are where this case is decided. Read them for the grade of the prior
biopsy (Gleason or ISUP), the number of biopsy sessions and their dates, and whether he is on a
surveillance protocol with a confirmatory biopsy due. Do not read this as 'defer' and do not read it
as 'biopsy'.

VARIABLES I WEIGHED — in the form's vocabulary, with this man's values (panel only; 'decisive' marks the variable the rule turns on)
  important  prior biopsy = Positive
  noted      age = 66 · DRE = Normal · PSA = 12 ng/mL · prostate volume = 69.24 mL · PSA density = 0.173 · PI-RADS = 5 · comorbidity = none recorded
  not used   family history, csPCa probability
CONFIDENCE: uncertain — none of my three panel rules applies; the fact that would settle it — the documented prior grade — lives in the notes, not on the panel

## Intervención 5 — EXPERT-LIBRARY

*case library; the closest labelled precedents and what the reading urologist did with them* · vuelta 1

The case library holds 49 labelled men in this same situation (Positive prior biopsy). The 3 closest by panel distance, and what the reading urologist did:
  1. distance 0.89: PI-RADS 5, PSA 11.0, PSAD 0.108, age 70, DRE Normal -> BIOPSY (borderline). He wrote: "Patient on Activ Surveillance with severe LUTS symptoms. There are two options , recommend surgery direkt or do a new biopsy."
  2. distance 1.02: PI-RADS 5, PSA 12.0, PSAD 0.28, age 61, DRE Normal -> DEFER (borderline). He wrote: "Young patient with elevated PSA (>10), elevated PSA density, PIRADS5 and ISUP GG2 disease -> low threshold for recommending curative treatment. IF patient does not want…"
  3. distance 1.02: PI-RADS 5, PSA 19.0, PSAD 0.37, age 65, DRE Normal -> DEFER (clear). He wrote: "Patient needs treatment without repeat biopsy as earlier biopsy showed ISUP4"

PRECEDENT: DEFER (weighted vote 0.36 for biopsy). Distance-weighted precedent is no better than chance here (0.47 leave-one-out): read the precedents for how this urologist reasons, not for the answer.

What the precedents are FOR: they show what this urologist looks at and how he phrases the call. What they are NOT: facts about this patient. Nobody may cite a precedent's grade, PSA or MRI as if it were his.

WHAT THE READING UROLOGIST WEIGHED IN THESE PRECEDENTS — in the form's vocabulary, with this man's values (weighted majority of the 3 nearest labelled traces; the distance itself is on PI-RADS, prior biopsy first)
  decisive   PI-RADS = 5
  important  prior biopsy = Positive · PSA = 12 ng/mL · prostate volume = 69.24 mL
  noted      family history = not opened (0 of 91) · age = 66 · DRE = Normal · PSA density = 0.173
  not used   csPCa probability, comorbidity
CONFIDENCE: uncertain — in this situation the library is no better than chance (47% out of fold)

## Intervención 6 — EXPERT-TRACE

*Expert 4, trace model; which documents the reading urologist opens and what he weighs in this situation* · vuelta 1

Expert 4 here — the model of how the reading urologist works a case like this. Predicted from his 49 labelled traces in this situation (Positive prior biopsy): a per-field model where it beats the mode out of fold (prior-biopsy weight, DRE weight, PI-RADS weight, and whether he opens the laboratory), the mode elsewhere.

WHAT HE OPENS: radiology_report, psa_trend, previous_notes.

WHAT HE WEIGHS — in the form's vocabulary, with this man's values (these are the levels that go on the form, unless a colleague shows a reason to move one)
  important  prior biopsy = Positive · age = 66 · PSA = 12 ng/mL · PI-RADS = 5
  noted      family history = not opened (0 of 91) · DRE = Normal · prostate volume = 69.24 mL · PSA density = 0.173 · comorbidity = none recorded
  not used   csPCa probability
CONFIDENCE: clear — the level the reading urologist records in this situation, from his labelled traces

MODERATOR: that list of documents is the plan — exactly those, no more. Every document opened beyond what
he would open is scored against the conference as an unnecessary reveal; every document left closed
leaves a variable he weighed without its source. Attach the question each one must answer.

## Intervención 7 — EXPERT-EAU

*EAU guideline specialist; speaks only from the guideline text he retrieved* · vuelta 1

GUIDELINE
"sion on MRI mandates a repeat biopsy to confirm histological progression before a change in treatment strategy."
This guideline suggests that a lesion on MRI mandates a repeat biopsy to confirm histological progression before changing treatment. It also notes that a stable MRI (PRECISE 1-3) does not make a repeat biopsy superfluous but it might be excluded in patients with low-risk tumour and a stable low PSA-D < 0.15.

WHAT THE EXPERTS' BIDS DO NOT SETTLE
EXPERT-STRUCTURED, EXPERT-COHORT, and EXPERT-LIBRARY all weighed the 'prior biopsy = Positive' variable as decisive or important. The guideline treats this as context, but the guideline suggests that the documented grade of the prior biopsy is what settles the decision, which is a fact the panel does not represent. The guideline requires the documented grade of the prior biopsy to settle the decision, which is a fact the panel does not represent. The guideline needs the documented grade of the prior biopsy to settle the decision, which is a fact the panel does not represent.

WHAT THE DOCUMENTS MUST SETTLE
previous_notes - the grade of the prior biopsy: at ISUP 2 or above the guideline sends him to treatment, not to more tissue; if it is unrecorded the indication stands
radiology_report - whether the lesion is compared against an earlier study: unchanged does not support re-sampling, new or larger does
psa_trend - whether the PSA has normalized: if the PSA has normalized, a new PSA test can be performed after one year
laboratory_results - whether the PSA density is low: if the PSA density is low, it might be excluded in patients with low-risk tumour
family-history anamnesis - whether the family history is present: if the family history is present, it might be included in risk factors

## Intervención 8 — MODERATOR

*chairs the discussion; sets the open questions and assigns the documents* · vuelta 1

The case hinges on the documented grade of the prior biopsy, which is contained within the previous notes, as the current panel is inconclusive.

The documents for this session were fixed by EXPERT-TRACE; what I add is the question each one has to answer, and the open questions for the room.

REGISTRAR — pull these up, and answer exactly the question attached to each:
  radiology_report (get_mri_report) -> Does the lesion on MRI need to be compared against an earlier study?
  psa_trend (get_psa_trend) -> Has the PSA normalized?
  previous_notes (get_previous_notes) -> What is the grade of the prior biopsy?

OPEN QUESTIONS for this conference — these are what the decision hangs on:
  Q1. What is the grade of the prior biopsy?
  Q2. Does the PSA have normalized?

## Intervención 9 — REGISTRAR

*the registrar who pulls up documents; reports what they say, nothing else* · vuelta 1

WHAT I FOUND
radiology_report
Subject: Multiparametric MRI Prostate | Institution: Radboudumc | Date: 10 Feb 2025
COMPARISON: new
LESION: PI-RADS 5 focus situated in the right mid-apical peripheral zone.

psa_trend
PSA 7.0 (Jan 2024) rising to 12.0 (Feb 2025), steepest in the last year.

previous_notes
PRIOR GRADE: not recorded
BIOPSY SESSIONS: not recorded
SURVEILLANCE: serial PSA tracking and symptom monitoring continued regularly.
TREATMENT: none recorded

WHAT I DID NOT OPEN
family-history anamnesis, because the decision hinges on the prior biopsy grade and PSA normalization, which are in the other documents.

WHAT THIS SUPPORTS
FOR sampling this patient now
PI-RADS 5 focus situated in the right mid-apical peripheral zone (from radiology_report)
PSA 12.0 (Feb 2025) (from psa_trend)

AGAINST sampling this patient now
prior biopsy grade is not recorded (from previous_notes)

WHERE THIS LEANS
LEAN: unclear

## Intervención 10 — EXPERT-PSA

*Expert 2, PSA projector; the trajectory behind the headline PSA, with a conformal band* · vuelta 1

Expert 2 here — the PSA projector. I read only the serial PSA the registrar opened.

TRAJECTORY: RISING (borderline). Last value 12.00 ng/mL over 4 points spanning 13 months; velocity +4.36 ng/mL per year; doubling time about 16 months.
PROJECTION at 6 months: 23.3 ng/mL, conformal 95% band 6.7-81.2.

Read the band before the point: it is wide by construction, and I only call a direction when the whole
band clears the last value. This does not vote on the biopsy — a rising PSA in a man with a known
diagnosis is the disease behaving as known — it tells the chair how fast the number is moving.

VARIABLES I WEIGHED — in the form's vocabulary, with this man's values (the serial PSA only)
  noted      PSA = 12 ng/mL
  not used   prior biopsy, family history, age, DRE, prostate volume, PSA density, csPCa probability, PI-RADS, comorbidity
CONFIDENCE: borderline — the conformal band does not clear the last value

## Intervención 11 — EXPERT-FUSION

*Expert 3, Extra-Trees on panel + laboratory + MRI prose; speaks only on documents that were opened* · vuelta 1

Expert 3 here — the fusion classifier. I read the panel, the mpMRI report — the laboratory panel was not opened, so that block is imputed and my band is wider for it; nothing from the previous notes or the PSA series.

SUGGESTION: BIOPSY   p(biopsy) = 0.60
  uncertainty  +/- 0.09 epistemic (95% band 0.42-0.78), of which 0.01 comes from values that had to be imputed
  reliability  MODERATE ('supports' tier) — out-of-fold it was right 56% of the time over the 25 labelled cases in this tier

VARIABLES I WEIGHED — in the form's vocabulary, with this man's values (panel + the documents that were opened; PI-RADS here means the report's own wording — DWI restriction, lesion size — not the score)
  decisive   prior biopsy = Positive (43% of my signal; from bx_positive, bx_none)
  important  PI-RADS = 5 (22% of my signal; from rad_dwi_restriction, rad_lesion_ge15mm)
  noted      PSA = 12 ng/mL (21% of my signal; from fpsa_lt15, psa_delta_prev) · prostate volume = 69.24 mL (4% of my signal; from log_vol, vol) · PSA density = 0.173 (0% of my signal; from psad_calc) · comorbidity = none recorded (4% of my signal; from n_comorbidities, on_alpha_blocker)
  not used   family history, age, DRE, csPCa probability
CONFIDENCE: borderline — 'supports' tier; out-of-fold it was right 56% of the time over the 25 labelled cases in this tier

Out-of-fold AUC 0.794. I am the only expert that has read the report's
wording, and I still cannot see the prior grade or the surveillance history: those are in the notes, and
the registrar has to carry them.

## Intervención 12 — PANEL-PROTOCOL

*the panel's written protocol; consolidates the experts by rule and says which rule fired* · vuelta 1

The panel protocol, applied to what is on the board:

  EXPERT-STRUCTURED  BIOPSY, p(biopsy)=0.60  ('supports' tier; weight 2.0)
  EXPERT-FUSION      BIOPSY, p(biopsy)=0.60  ('supports' tier, fusion_nolab; weight 3.0)
  EXPERT-LIBRARY     DEFER, p(biopsy)=0.36  (k=3 precedents; does not vote)

  documented prior grade in the opened documents: none recorded

RULE THAT FIRED: weighted vote of the trained experts, p = 0.60 — carried by weighted panel.
PANEL ANSWER: BIOPSY. EXPERT-FUSION carried the most weight ('supports' tier, fusion_nolab). In this bucket no rule applied and the documents did not record the prior grade, so the trained experts decide.
Dissenting on the board: EXPERT-LIBRARY. Their bids are recorded above; they did not carry because a higher rung of the protocol applied.

THE BOARD'S VARIABLES — value · what each expert marked · what goes on the form
  bx           Positive                     E1:DEC E3:DEC cohort:IMP library:IMP E2:—            -> important
  fh           not opened (0 of 91)         E1:— E3:— cohort:— library:not E2:—                  -> not_used (raised from noted by the board)
  age          66                           E1:not E3:— cohort:not library:not E2:—              -> important
  dre          Normal                       E1:not E3:— cohort:not library:not E2:—              -> not_used (raised from noted by the board)
  psa          12 ng/mL                     E1:not E3:not cohort:not library:IMP E2:not          -> important
  vol          69.24 mL                     E1:not E3:not cohort:not library:IMP E2:—            -> noted
  psad         0.173                        E1:not E3:not cohort:not library:not E2:—            -> noted
  cspca        0.85                         E1:not E3:— cohort:— library:— E2:—                  -> not_used
  pirads       5                            E1:not E3:IMP cohort:not library:DEC E2:—            -> important
  comorbidity  none recorded                E1:IMP E3:not cohort:not library:— E2:—              -> noted
  (DEC decisive · IMP important · not noted · — not used; the last column is the level recorded, from the trace of the reading urologist)

Confidence to record: clear.

CHAIR: this is the panel's position. You sign it, and you write why in the room's words — naming what the registrar retrieved. If you believe a retrieved finding overturns it, name that finding with its value; the burden is on the finding, not on the panel.

## Intervención 13 — VERIFIER

*second EAU reader; checks against the guideline whether this can be decided yet* · vuelta 1

SUFFICIENCY
The documents the registrar opened (radiology_report, psa_trend, previous_notes) address the moderator's questions to some extent, but the critical information remains missing.

ALIGNMENT WITH THE PANEL
The PANEL-PROTOCOL concludes BIOPSY based on a weighted vote (p=0.60), but this decision rests on the fact that the "documented prior grade in the opened documents: none recorded." This aligns with the guideline's requirement that the documented grade settles the decision, which is not met.

THE OPEN QUESTIONS, ONE BY ONE
Q1. What is the grade of the prior biopsy? This question is unanswered, as the previous_notes state "PRIOR GRADE: not recorded." Q2. Does the PSA have normalized? This question is unanswered, as the psa_trend shows a rising trend, not normalization.

WHAT CARRIES WEIGHT, AND WHY
<prior biopsy>: not_used / not recorded because the previous_notes explicitly state "PRIOR GRADE: not recorded," which is the key missing piece the guideline requires to settle the decision. <psa>: important / 12 ng/mL because the PSA value is noted, and the trajectory is rising, which is relevant to the clinical context. <pirads>: important / 5 because the PI-RADS score is important, and the EXPERT-COHORT marks it important. My confidence in the record as it stands is borderline.

MY SUGGESTION TO THE CHAIR
Given that the critical variable—the prior biopsy grade—is explicitly not recorded in the retrieved notes, the panel's decision to BIOPSY is based on expert consensus rather than guideline-driven evidence. I suggest deferring until the prior biopsy grade is obtained, as the guideline states this fact is what settles the decision.

VERDICT: not-ready | SUGGEST: defer | MISSING: previous_notes

[The conference closes after pass 1: every document on the plan is open; nothing outside the plan is ever opened. The chair decides on the record as it stands.]

## Intervención 14 — CHAIR

*the senior urologist who signs the decision* · vuelta 1

MY DECISION: BIOPSY   (confidence: clear)

66y male, PSA 12.0, PI-RADS 5, prior biopsy grade not recorded. Given the new PI-RADS 5 finding and unrecorded prior grade, sampling is indicated to determine management pathway. The rising PSA trend and unrecorded prior biopsy grade necessitate tissue confirmation before proceeding with surveillance.

What carried weight: bx=important, age=important, psa=important, vol=noted, psad=noted, pirads=important, comorbidity=noted
Sections retrieved: radiology_report, psa_trend, previous_notes
